BBIO · BridgeBio Pharma Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.63B |
| P/E | — |
| Float | 171.5M |
| Beta | 0.96 |
| Volatility | 24.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74 |
| Price | 74.84 |
| Change | +0.00% |
| Prev Close | 74.84 |
| Open | 74.98 |
| Day Low | 74.11 |
| Day High | 75.36 |
| Avg Vol | 2 |
| Avg $ Vol | $112.4M |
| 52W High | 93.42 |
| 52W Low | 48.78 |
| 52W Pos | 58.4% |
| From High | −19.88% |
| From Low | +53.42% |
| Max DD 1Y | −20.25% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −6.48% |
| SMA 50 | −7.15% |
| SMA 200 | +1.35% |
| RSI (14) | 32.2 |
| Vol 30D | 25.2% |
| Vol 90D | 39.5% |
| 1Y Range | 49–93 |
| Daily bars | 886 |
| Perf Week | −2.30% |
| Perf Month | −9.61% |
| Perf Quarter | +10.69% |
| Perf Half Y | +14.50% |
| Perf Year | +44.40% |
| Perf YTD | −4.34% |
| Prev Day | +0.00% |
| Clavix | B |
| Debt / Eq | 8.27 |
| Curr Ratio | 2.77 |
| Int Cover | -1.9× |
| FCF Margin | — |
| Rev Growth | +120.4% |
| Profit | Unprofitable |
| Leverage | Very High |
| Sector rank | 12 / 35 |
Clavix risk grade
regraded every trading dayBBIO grades B, 74 of 100. Steadiest on Macro Resilience (65), most exposed on News Sentiment (40, fragile). 1 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 12 of 35 in Biotechnology by Clavix score.
How rough the ride is
| BBIO | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.96 | 0.50 |
| Volatilityannualized | 24.0% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −20.2% | — |
| Typical daily movemedian absolute daily change | 1.43% | — |
| Days beyond ±3%of the last 252 sessions | 4919% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BBIO | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.96 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BBIO | |
|---|---|
| 1 week | −2.3% |
| 1 month | −9.6% |
| Year to date | −4.3% |
| 1 year | +44.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BBIO | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 3 Aug |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 5 |
| Directionarticles whose tone is improving vs worsening | 15 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| BBIO | |
|---|---|
| Revenue growthyear over year | +120.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | BBIO | Sector spread | Median |
|---|---|---|---|
| Beta | 0.96 | 0.50 | |
| Volatility | 24.0% | 13.2% | |
| Debt / equity | 8.27 | 0.24 | |
| Current ratio | 2.77 | 3.73 | |
| Interest coverage | -1.9× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openBridgeBio reported new cardiac MRI scans from its Phase 3 ATTRibute-CM trial of acoramidis in ATTR-CM (a heart disease where abnormal protein builds up in the heart muscle), suggesting some patients showed actual improvement in heart structure and function, not just stabilization. A separate post-hoc analysis also indicated the treatment preserved more cardiac tissue. The article's headline flags uncertainty about how much to read into this 'completer analysis.'
HC Wainwright analyst R. Selvaraju lowered his earnings per share (EPS) estimate for BridgeBio Pharma for the third quarter of 2026, according to a research note issued to investors on Wednesday, September 2nd. The article is truncated and does not provide the prior or revised EPS figures.
President Trump announced drug pricing agreements with nine more pharmaceutical companies, including BridgeBio, bringing the total to 26 companies. The deals aim to bring U.S. drug prices closer to the lower prices charged in other countries.
BridgeBio Pharma has voluntarily agreed with the U.S. government to expand access to its medicines and lower drug costs for American patients, using a new pricing and reimbursement model for Medicaid. Medicare Part D products keep their current terms, and drugs for rare diseases (orphan indications) are exempt from future pricing commitments.
An analyst commentary argues that BridgeBio's stock, which has gained 158.6% over three years, now looks fairly valued rather than cheap despite fresh data on its heart drug acoramidis.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| EXEL | Exelixis Inc | B+ | $14.62B | 16.99 | 0.48 | Compare |
| NBIX | Neurocrine Biosciences Inc | B | $15.82B | 22.42 | 0.36 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $16.88B | 19.59 | 0.38 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.51B | 30.24 | 0.96 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.50B | — | -1.10 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $12.20B | — | 1.30 | Compare |
| KRYS | Krystal Biotech Inc | B | $10.60B | 43.91 | 0.55 | Compare |
| CYTK | Cytokinetics Inc | B | $10.11B | — | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.